# To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .

> **NCT06168383** · PHASE2 · COMPLETED · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 186 (actual)

## Conditions studied

- Non-Alcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** HSK31679 80mg
- **DRUG:** HSK31679 160mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06168383
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-05
- **Primary completion:** 2025-12-12
- **Final completion:** 2026-01-16
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06168383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06168383, "To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06168383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*